Patents Assigned to Amarillo Biosciences, Inc.
-
Publication number: 20210113777Abstract: A smart drug injection device is disclosed, comprising a main body, a circuit board, a display, a syringe and a transmission mechanism; the main body comprises an accommodating space and a power button; the circuit board comprises a control unit and a storage unit; the transmission mechanism comprises a motor, a screw rod, a propelling block and a movable clamp, with the control unit electrically connected to the storage unit, the power button, the motor and the display, the motor connected to the screw rod, the propelling block movably arranged on the screw rod, the movable clamp disposed at one end of the propelling block and movable between two positions; the syringe is on one side of the main body and comprises a cylinder and a needle holder, one end of the cylinder has a needle and the other end is assembled with the needle holder.Type: ApplicationFiled: October 13, 2020Publication date: April 22, 2021Applicant: AMARILLO BIOSCIENCES, INCInventors: Stephen T. CHEN, Hsien-Yao CHIU
-
Patent number: 9839672Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.Type: GrantFiled: August 3, 2017Date of Patent: December 12, 2017Assignee: Amarillo Biosciences, Inc.Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
-
Patent number: 9750786Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.Type: GrantFiled: October 31, 2016Date of Patent: September 5, 2017Assignee: Amarillo Biosciences, Inc.Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
-
Patent number: 9526694Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.Type: GrantFiled: April 30, 2013Date of Patent: December 27, 2016Assignee: Amarillo Biosciences, Inc.Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
-
Publication number: 20070237723Abstract: A method of treating chronic coughing in a patient comprising administering to the patient an effective amount of interferon; a method of treating idiopathic pulmonary fibrosis in a patient comprising orally administering to the patient a composition comprising interferon.Type: ApplicationFiled: March 29, 2007Publication date: October 11, 2007Applicant: AMARILLO BIOSCIENCES, INC.Inventors: Joseph M. Cummins, Martin J. Cummins
-
Patent number: 6656920Abstract: The present invention relates to a method for increasing unstimulated whole saliva in a patient. The method comprises orally administering an effective amount of a disaccharide, such as maltose, trehalose, or anhydrous crystalline maltose, to the patient in a dosage form such as a lozenge. The disaccharide can also be administered in combination with an effective amount of vitamin C, or a derivative thereof, such as a vitamin C ester. The invention is also directed to a pharmaceutical composition comprising a disaccharide in combination with vitamin C, or a derivative thereof, such as a vitamin C ester. The method is used to treat diseases such as Sjögren's syndrome and xerostomia.Type: GrantFiled: April 4, 2001Date of Patent: December 2, 2003Assignee: Amarillo Biosciences, Inc.Inventors: Philip C. Fox, Martin J. Cummins, Joseph M. Cummins
-
Patent number: 6506377Abstract: A method for enhancing the expression of aquaporin proteins by contacting aquaporin producing cells with interferon-&agr; is described. The method enables treatment of patients afflicted with disease states characterized by xerosis.Type: GrantFiled: September 27, 2001Date of Patent: January 14, 2003Assignees: Amarillo Biosciences, Inc., East Tennessee State UniversityInventors: Joseph M. Cummins, J. Kelly Smith
-
Patent number: 6036949Abstract: A method is described for using interferon in the treatment of human patients afflicted with fibromyalgia to alleviate one or more symptoms associated with that disease state. Fibromyalgia positive patients treated buccally, sublingually or by oral ingestion administration of low doses of interferon enjoy a reduction in clinical symptoms of the disease.Type: GrantFiled: March 5, 1998Date of Patent: March 14, 2000Assignee: Amarillo Biosciences, Inc.Inventors: Alan B. Richards, Edward Sherwood